The Clinton Drug Price Board, 23 Years Later
Hillary Clinton is reviving an idea she first endorsed in 1993: a drug price oversight board, but the focus has changed. While the pharma industry isn’t about to embrace any federal oversight board, the new Clinton plan is a lot less threatening than the old one.
You may also be interested in...
Drug pricing is bound to be a dominant theme in the 2020 Democratic primaries and US Presidential election. But there are some differences in the crowded field of candidates, including several who are more likely to emphasis protecting innovation alongside controlling prices.
Plan would empower new agency to investigate and potentially fine drug manufacturers that make unjustified price increases.
Legislation like FAIR drug pricing bill, which requires sponsors to justify price increases over 10%, could ultimately discourage generic competition since it could burden ANDA sponsors for even small dollar increases, GPhA CEO Davis argues.